4.8 Article

Two factor authentication: Asf1 mediates crosstalk between H3 K14 and K56 acetylation

期刊

NUCLEIC ACIDS RESEARCH
卷 47, 期 14, 页码 7380-7391

出版社

OXFORD UNIV PRESS
DOI: 10.1093/nar/gkz508

关键词

-

资金

  1. National Institutes of Health (NIH) [R01 GM102503, T32CA009035-36A1]
  2. Johnson Johnson
  3. NIH

向作者/读者索取更多资源

The ability of histone chaperone Anti-silencing factor 1 (Asf1) to direct acetylation of lysine 56 of histone H3 (H3K56ac) represents an important regulatory step in genome replication and DNA repair. InSaccharomyces cerevisiae, Asf1 interacts functionally with a second chaperone, Vps75, and the lysine acetyltransferase (KAT) Rtt109. Both Asf1 and Vps75 can increase the specificity of histone acetylation by Rtt109, but neither alter selectivity. However, changes in acetylation selectivity have been observed in histones extracted from cells, which contain a plethora of post-translational modifications. In the present study, we use a series of singly acetylated histones to test the hypothesis that histone pre-acetylation and histone chaperones function together to drive preferential acetylation of H3K56. We show that pre-acetylated H3K14ac/H4 functions with Asf1 to drive specific acetylation of H3K56 by Rtt109-Vps75. Additionally, we identified an exosite containing an acidic patch in Asf1 and show that mutations to this region alter Asf1-mediated crosstalk that changes Rtt109-Vps75 selectivity. Our proposed mechanism suggests that Gcn5 acetylates H3K14, recruiting remodeler complexes, allowing for the Asf1-H3K14ac/H4 complex to be acetylated at H3K56 by Rtt109-Vps75. This mechanism explains the conflicting biochemical data and the genetic links between Rtt109, Vps75, Gcn5and Asf1 in the acetylation of H3K56.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells

Somnath Pandey, Rahinatou Djibo, Anais Darracq, Gennaro Calendo, Hanghang Zhang, Ryan A. Henry, Andrew J. Andrews, Stephen B. Baylin, Jozef Madzo, Rafael Najmanovich, Jean-Pierre J. Issa, Noel J-M Raynal

Summary: By combining drug screens, transcriptomic studies, and in vitro assays, our study identified toyocamycin as a potent and selective CDK9 inhibitor. Toyocamycin exhibits specific CDK9 inhibition in cancer cells and has the potential for cancer chemotherapy.

CANCERS (2022)

暂无数据